Correspondence 0000950170-24-105596 from Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc.
Date: Sept. 11, 2024 · CIK: 0001671584 · Accession: 0000950170-24-105596

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-281892

Date

September 11, 2024

Author

Marvin L. White

Form

CORRESP

Company

Aptevo Therapeutics Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 File No. 333-281892

Dear Ms. Gama:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-281892) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on September 12, 2024, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

Very truly yours,
Aptevo Therapeutics Inc.

Show Raw Text

CORRESP
1
filename1.htm

  CORRESP

  September 11, 2024

  VIA EDGAR

  United States Securities and Exchange Commission

  Division of Corporation Finance

  Office of Life Sciences

  100 F Street, N.E.

  Washington, D.C. 20549

  Attention: Ms. Doris Stacey Gama

  Re: Aptevo Therapeutics Inc.

  Registration Statement on Form S-1
File No. 333-281892

  Dear Ms. Gama:

  In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-281892) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on September 12, 2024, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

  Very truly yours,

  Aptevo Therapeutics Inc.

  By: /s/ Marvin L. White

  Marvin L. White

  President and Chief Executive Officer

    CC:

    SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP

SecProbe.io